1. Home
  2. MARPS vs APRE Comparison

MARPS vs APRE Comparison

Compare MARPS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marine Petroleum Trust Units of Beneficial Interest

MARPS

Marine Petroleum Trust Units of Beneficial Interest

HOLD

Current Price

$4.38

Market Cap

9.9M

Sector

Energy

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.81

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARPS
APRE
Founded
1956
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
11.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MARPS
APRE
Price
$4.38
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
10.7K
116.3K
Earning Date
02-13-2026
05-13-2026
Dividend Yield
6.95%
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.05
$0.55
52 Week High
$6.49
$2.22

Technical Indicators

Market Signals
Indicator
MARPS
APRE
Relative Strength Index (RSI) 39.52 50.56
Support Level $4.16 $0.75
Resistance Level $4.88 $0.81
Average True Range (ATR) 0.17 0.07
MACD -0.01 0.01
Stochastic Oscillator 24.29 76.10

Price Performance

Historical Comparison
MARPS
APRE

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: